The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge
Open accessAbstract
Gene based delivery of immunoglobulins promises to safely and durably provide protective immunity to individuals at risk of acquiring infectious diseases such as HIV. We used a rhesus macaque animal model to optimize delivery of naturally-arising, autologous anti-SIV neutralizing antibodies expressed by Adeno-Associated Virus 8 (AAV8) vectors. Vectored transgene expression was confirmed by quantitation of target antibody abundance in serum and mucosal surfaces. We tested the expression achieved at varying doses and numbers of injections. Expression of the transgene reached a saturation at about 2 x 10(12) AAV8 genome copies (gc) per needle-injection, a physical limitation that may not scale clinically into human trials. In contrast, expression increased proportionately with the number of injections. In terms of anti-drug immunity, anti-vector antibody responses were universally strong, while those directed against the natural transgene mAb were detected in only 20% of animals. An anti-transgene antibody response was invariably associated with loss of detectable plasma expression of the antibody. Despite having atypical glycosylation profiles, transgenes derived from AAV-directed muscle cell expression retained full functional activity, including mucosal accumulation, in vitro neutralization, and protection against repeated limiting dose SIVsmE660 swarm challenge. Our findings demonstrate feasibility of a gene therapy-based passive immunization strategy against infectious disease, and illustrate the potential for the nonhuman primate model to inform clinical AAV-based approaches to passive immunization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In one study, re-administration of AAV8 in NHP did not result in increased transgene expression, but increased anti-AAV antibody levels were observed [75].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Self-citationHemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
Kelley, B. (2009) · mAbs · doi:10.4161/mabs.1.5.9448 · Cited by 667
Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays
Montefiori, D. C. (2004) · Current Protocols in Immunology · doi:10.1002/0471142735.im1211s64 · Cited by 580
Research works printed but not linked: 2
- D Gaudet, 2013, Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial, Gene Ther. Macmillan Publishers Limited, 20, 361
- KO Saunders, 2015, Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection, J Virol, 89, 5895, 10.1128/JVI.00210-15 · DOI
Cited by
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“In one study, re-administration of AAV8 in NHP did not result in increased transgene expression, but increased anti-AAV antibody levels were observed [75].”
BackgroundPegu, A., Borate, B. R., Huang, Y., Pauthner, M. G., Hessell, A. J., Jülg, B. D., Doria‐Rose, N. A., Schmidt, S. D., Carpp, L. N., Cully, M. D., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.08.014 · Cited by 122
Self-citationCasazza, J. P., Cale, E. M., Narpala, S., Yamshchikov, G. V., Coates, E. E., Hendel, C. S., Novik, L., Holman, L. A., Widge, A. T., Apte, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01762-x · Cited by 91
Self-citationAdvancements in mRNA Encoded Antibodies for Passive Immunotherapy
Deal, C. E., Carfí, A., & Plante, O. J. (2021) · Vaccines · doi:10.3390/vaccines9020108 · Cited by 91
“Dose escalation studies demonstrated increasing serum concentrations of ZIKV-117 as the dose escalated to 10 μg of mRNA, after which there was no significant increase, likely due to saturation of protein production from cells at the injection site and innate immune activation [85].”
BackgroundAAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges
Gardner, M. R., Fellinger, C. H., Kattenhorn, L. M., Davis-Gardner, M. E., Weber, J. A., Alfant, B., Zhou, A. S., Prasad, N. R., Kondur, H. R., Newton, W., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5409 · Cited by 56
Self-citation
Metadata
- Authors
- Welles, H. C., Jennewein, M. F., Mason, R. D., Narpala, S., Wang, L., Cheng, C., Zhang, Y., Todd, J.-P., Lifson, J. D., Balazs, A. B., Alter, G., McDermott, A. B., Mascola, J. R., & Roederer, M.
- Affiliations
- National Institutes of Health (US)
- Ragon Institute of MGH, MIT and Harvard (US)
- Frederick National Laboratory for Cancer Research (US)
- Corresponding author
- Welles, Hugh C.
- Jennewein, Madeleine F.
- Mason, Rosemarie D.
- Narpala, Sandeep
- Wang, Lingshu
- Cheng, Cheng
- Zhang, Yi
- Todd, John-Paul
- Lifson, Jeffrey D.
- Balazs, Alejandro B.
- Alter, Galit
- McDermott, Adrian B.
- Mascola, John R.
- Roederer, Mario
- ORCID
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-12-05
- Volume
- 14
- Issue
- 12
- Pages
- e1007395
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC6296672
- OpenAlex
- W2902838323
- Cited by
- 53
- References
- 73
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 4 · 2023: 10 · 2022: 7 · 2021: 8 · 2020: 5 · 2019: 8
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Update notices
- new_version (2018-12-17)
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- PLoS Pathogens (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Frederick National Laboratory for Cancer Research
- National Institutes of Health (HHSN261200800001C)
- National Institute on Drug Abuse (DP2DA040254)
- National Cancer Institute (HHSN261200800001E))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- AAV8 vector, gene therapy, passive immunization, rhesus monkeys, intrarectal challenge, HIV prevention, glycosylation, nonhuman primate model
- MeSH terms
- Dependovirus, Animals, Antibodies, Monoclonal, Antibodies, Viral, Genetic Vectors, Immunization, Passive, Macaca mulatta, Viral Envelope Proteins, Simian Immunodeficiency Virus, Genetic Therapy, Simian Acquired Immunodeficiency Syndrome, SAIDS Vaccines, Transgenes, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. https://app.cochat.ai/papers/10.1371/journal.ppat.1007395
- The paper
- Welles, H. C., Jennewein, M. F., Mason, R. D., Narpala, S., Wang, L., Cheng, C., Zhang, Y., Todd, J.-P., Lifson, J. D., Balazs, A. B., Alter, G., McDermott, A. B., Mascola, J. R., & Roederer, M. (2018). Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1007395
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.